The latest discoveries in Neurology
A concise briefing on the most relevant research developments in your field, curated for clarity and impact.
A new drug target emerges for halting progression in a severe form of multiple sclerosis
A phase II trial has demonstrated promising results for nasal foralumab, an anti-CD3 monoclonal antibody, in treating nonactive secondary progressive multiple sclerosis (SPMS). The study focused on patients experiencing progression independent of relapses (PIRA), a challenging clinical course where disability accumulates without new inflammatory attacks. Early findings suggest the treatment, delivered intranasally to target brain inflammation, may slow disability progression in this patient population, offering a potential new therapeutic avenue where options are currently limited.
Why it might matter to you:
This trial represents a direct clinical advance in managing progressive MS, a core area of neurodegeneration. The mechanism—modulating brain-specific immune responses via an intranasal route—could inform the development of other targeted CNS therapies. For biomarker research, understanding the pharmacodynamic effects of such agents is crucial for validating companion diagnostic assays that track therapeutic efficacy beyond conventional clinical scales.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.